<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155125</url>
  </required_header>
  <id_info>
    <org_study_id>GXE4KGBio-001</org_study_id>
    <nct_id>NCT04155125</nct_id>
  </id_info>
  <brief_title>A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient</brief_title>
  <official_title>Open-Label Randomised Controlled Trial of Efepoetin Alfa for Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not on Dialysis (ND-CKD). A Non- Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Kalbe Genexine Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PT Kalbe Genexine Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomised, multicenter, Mircera-controlled, parallel-group, Phase III&#xD;
      study to determine whether subcutaneous administered efepoetin alfa is as effective and well&#xD;
      tolerated as subcutaneous Mircera for anaemia correction and maintenance in erythropoiesis&#xD;
      stimulating agent (ESA)-naïve subjects who have CKD and are not on dialysis. ESA prior users&#xD;
      who have stopped using ESA at least 12 weeks till screening will also be eligible for this&#xD;
      study provided they fulfil all the subject entry criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a 20-week correction period for dosage titration and Hb correction,&#xD;
      followed by an 8-week evaluation period for efficacy assessments of corrective treatment.&#xD;
      Subjects who respond to efepoetin alfa (defined as an increase in Hb ≥1.0 g/dL versus&#xD;
      baseline and Hb level within 10 - 12 g/dL range without blood transfusion during the 28 weeks&#xD;
      after the first dose) will be eligible to continue treatment, and will be randomised to&#xD;
      receive subcutaneous efepoetin alfa either once every 2W or every 4W for an additional&#xD;
      24-week extension period to assess long-term safety and maintenance effect. Mircera&#xD;
      responders will also be allowed to continue the drug during the extension period, receiving&#xD;
      it every 4 weeks using the dose equal to twice the previous once-every-two-week dose. The&#xD;
      safety data collected will be part of an ongoing pooled analysis of safety data from the&#xD;
      efepoetin alfa clinical development program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of efepoetin alfa in the treatment of anaemia associated with CKD as measured by haemoglobin (Hb) response rate at the end of correction treatment evaluation period</measure>
    <time_frame>Measurement from the date of Randomization till the End of the Corrective Treatment period, assessed up to 20 weeks.</time_frame>
    <description>Measurement is done by an increase in Hb more than or equal to 1 g/dL compared with baseline and a Hb concentration within range of 10 - 12 g/dL inclusive without transfusion during evaluation period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterise safety and tolerability of subcutaneous efepoetin alfa is being measured by based on the frequency of adverse events and on the number of out of range laboratory values.</measure>
    <time_frame>Measurement from the time the subject provides informed consent through and including 28 calendar days after the last study drug administration.</time_frame>
    <description>Safety endpoints parameters including Serious Adverse Events (SAE) specified below&#xD;
Composite outcome of cardiovascular death or a nonfatal myocardial infarction or stroke&#xD;
All-cause mortality&#xD;
Cardiovascular mortality&#xD;
Acute myocardial infarction&#xD;
Heart failure&#xD;
Acute kidney injury defined according to Acute Kidney Injury Network (AKIN) criteria&#xD;
Abnormal clinical laboratory tests (haematology, biochemistry including serum ferritin and TSAT)&#xD;
Anti-efepoetin alfa or anti-Mircera antibody titres&#xD;
Clinically meaningful abnormal findings of vital signs&#xD;
Development of clinically meaningful electrocardiogram abnormalities&#xD;
Hospitalisations (excluding those for logistic reasons)&#xD;
It is a composite outcome. Any abnormal test findings during the study will be helpful in reviewing the outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Anaemia Associated With Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>efepoetin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route of administration: Subcutaneous Injection.&#xD;
The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mircera</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Route of administration: Subcutaneous Injection.&#xD;
The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efepoetin alfa</intervention_name>
    <description>The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.</description>
    <arm_group_label>efepoetin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mircera</intervention_name>
    <description>The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.</description>
    <arm_group_label>Mircera</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age should be greater than or equal to the minimum age of consent in the applicable&#xD;
             country&#xD;
&#xD;
          2. Stage 3 or 4 CKD (eGFR ≥ 15 and &lt; 60 mL/min/1.73 m2)&#xD;
&#xD;
          3. ESA-naive (no prior ESA use) subjects whose Hb at baseline is ≥ 8 g/dL and &lt; 10 g/dL,&#xD;
             or ESA prior users whose Hb at baseline is ≥ 8 g/dL and &lt; 10 g/dL and who have stopped&#xD;
             using ESA at least 12 weeks till the screening&#xD;
&#xD;
          4. Ferritin ≥ 100 ng/mL and transferrin saturation (TSAT) ≥ 20%&#xD;
&#xD;
          5. Subject must be willing to complete all study-related activities and follow-up visits&#xD;
&#xD;
          6. Evidence of a signed and dated informed consent document indicating that the subject&#xD;
             has been informed of all pertinent aspects of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Need for dialysis therapy expected in the next 12 months or rapid progression of CKD&#xD;
             (e.g., eGFR decrease of &gt;20% within 12 weeks)&#xD;
&#xD;
          2. Received a blood transfusion (including RBC transfusion) within the 12 weeks prior to&#xD;
             screening, or blood transfusion is anticipated during the study period&#xD;
&#xD;
          3. Have a history of overt gastrointestinal bleeding or any other bleeding episode&#xD;
             associated with a fall in Hb of ≥ 1 g/dL, within the last 8 weeks prior to screening&#xD;
&#xD;
          4. Have an unstable Hb for any reason, in the investigator's opinion&#xD;
&#xD;
          5. Have non-renal anaemia (any anaemia where the investigator considers the anaemia is&#xD;
             predominantly due to a non-renal cause. Non-renal causes include, but are not limited&#xD;
             to vitamin B12 or folic acid deficiency, homozygous sickle-cell disease, thalassemia&#xD;
             of all types, other non-renal cause of anaemia such as myelodysplasia or&#xD;
             haematological malignancies)&#xD;
&#xD;
          6. Platelet count of ≤ 50 x109/L&#xD;
&#xD;
          7. Vitamin B12 deficiency defined as total serum levels of &lt; 181 pmol/L (246 pg/ml) 10&#xD;
&#xD;
          8. Folic acid deficiency defined as total serum levels &lt; 7.63 nmol/L (3.37 ng/mL) 10&#xD;
&#xD;
          9. Pure red cell aplasia, or a history of pure red cell aplasia&#xD;
&#xD;
         10. Poorly controlled hypertension defined as a sitting SBP ≥170 mmHg and/or DBP ≥100 mm&#xD;
             Hg&#xD;
&#xD;
         11. Chronic congestive heart failure (New York Heart Association class IV) or are&#xD;
             otherwise at high risk for early withdrawal or interruption of the study (due to&#xD;
             myocardial infarction, severe or unstable coronary artery disease, stroke, or severe&#xD;
             liver disease) within the 12 weeks before screening or during screening&#xD;
&#xD;
         12. Active or not active malignancy (except non-melanoma skin cancer) within five years&#xD;
             before screening&#xD;
&#xD;
         13. Planned live kidney transplantation scheduled within 52 weeks after the screening&#xD;
             visit&#xD;
&#xD;
         14. Uncontrolled hyperparathyroidism, in the investigator's opinion&#xD;
&#xD;
         15. Uncontrolled hypothyroidism determined by the investigator that they cannot&#xD;
             participate in the study&#xD;
&#xD;
         16. Active acute or chronic infection, or uncontrolled or symptomatic inflammatory disease&#xD;
             (e.g., rheumatoid arthritis, systemic lupus erythematosus), or a C-reactive protein&#xD;
             level &gt; 15 mg/L. (Routinely screening for hepatitis B virus (HBV), hepatitis C virus&#xD;
             (HCV), and human immunodeficiency virus (HIV) infection is not required in this&#xD;
             protocol. By history or current clinical evidence, patients with active acute HBV or&#xD;
             HCV infection should be excluded. Chronic HBV/HCV infection with LFTs &gt; 3 times of&#xD;
             normal are excluded. Known HIV positive patients are excluded)&#xD;
&#xD;
         17. Immunosuppressive therapy (other than corticosteroids for a chronic condition, or&#xD;
             tacrolimus/cyclosporine) within 12 weeks prior to baseline&#xD;
&#xD;
         18. Life expectancy of less than 52 weeks&#xD;
&#xD;
         19. Planned surgery during the study period (excluding minor skin excisions)&#xD;
&#xD;
         20. Have received investigational drug(s) other than those of this study within 4 weeks&#xD;
             prior to screening, or will receive investigational drug(s) other than those of this&#xD;
             study during the study period&#xD;
&#xD;
         21. History or clinical evidence of cardiovascular, haematologic or hepatic (ALT, AST,&#xD;
             bilirubin values above three times the upper limit of normal [ULN] at screening) or&#xD;
             any physical conditions that, in the opinion of the investigator, would compromise&#xD;
             participation in the study&#xD;
&#xD;
         22. With a cognitive or psychiatric condition rendering the subject unable to be&#xD;
             cooperative with and complete study requirements&#xD;
&#xD;
         23. Hypersensitivity to any one of the investigational drugs&#xD;
&#xD;
         24. Subjects are, in the judgement of the investigator, otherwise inappropriate for entry&#xD;
             into the study&#xD;
&#xD;
         25. Subjects who are investigational site staff members directly involved in the conduct&#xD;
             of the trial and their family members, site staff members otherwise supervised by the&#xD;
             Investigator, or subjects who are KGBio or CRO employees directly involved in the&#xD;
             conduct of the trial&#xD;
&#xD;
         26. Participation in other studies involving same investigational drug(s) (Phases 1-4) of&#xD;
             this study within 12 weeks before screening&#xD;
&#xD;
         27. Females of childbearing potential or males who are unable/unwilling to take adequate&#xD;
             contraceptive precautions defined by the protocol for the duration of the study and&#xD;
             for at least 28 days after last dose of investigational product. Females have a&#xD;
             positive pregnancy test result within 24 hours prior to study entry, is otherwise&#xD;
             known to be pregnant, plans to become pregnant in the next 12 months or is currently&#xD;
             breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Srinivas Rao Jada</last_name>
    <phone>+6598474170</phone>
    <email>jada.rao@kalbe.co.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paritosh Keertikar</last_name>
    <phone>+6597306165</phone>
    <email>paritosh.keertikar@innogene.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renal Research Gosford</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Maxwell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jobert Angelo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JENNY SHEPHERD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seri Manjung Hospital</name>
      <address>
        <city>Seri Manjung</city>
        <state>Perak</state>
        <zip>32040</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lailye Zuraida</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Selangor</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Chaw</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Permaisuri Bainun</name>
      <address>
        <city>Ipoh</city>
        <zip>30450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalpana Devi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Kajang</name>
      <address>
        <city>Kajang</city>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sadanah Mazlan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Perempuan Zainab II</name>
      <address>
        <city>Kota Bharu</city>
        <zip>15200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siti Abdullah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Zaimi Wahab</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Tengku Ampuan Afzan</name>
      <address>
        <city>Kuantan</city>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohd Ahmad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Serdang</name>
      <address>
        <city>Serdang</city>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siti Daud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sibu</name>
      <address>
        <city>Sibu</city>
        <zip>96000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Yung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>M3 Dialysis Center</name>
      <address>
        <city>Bacolod City</city>
        <zip>6100</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Villaflor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baguio General Hospital Medical Center</name>
      <address>
        <city>Baguio</city>
        <zip>2600</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domigo Solimen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norzel Medical and Diagnostic Clinic</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Asis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>De La Salle Medical and Health Sciences Institute</name>
      <address>
        <city>Dasmariñas</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorna Dejucos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davao Doctors Hospital</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Aquitania</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Visayas State University Hospital</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rey Isidto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Kidney and Transplant Institute</name>
      <address>
        <city>Quezon</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Gumba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hualien Tzu Chi Hospital</name>
      <address>
        <city>Hualien City</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bang-Gee Hsu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Wen Chiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang-Ju Chou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Bor Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I-Wen Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taiching Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Hsu Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuang Tien General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>433</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherry Chung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan</city>
        <zip>433</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Chih Kan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junne-Ming Sung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauling Chu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Sen Peng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University - Shuang Ho Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya-Yun Hsu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Chieh Hung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vajira Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanjak Pongsittisak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kraiwiporn Kiattisunthorn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kajohnsak Noppakun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Pathum Thani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pajaree Krisanapan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pornpen Sangthawan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunpasitthiprasong Hospital</name>
      <address>
        <city>Ubon Ratchathani</city>
        <zip>34000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phisitt Vejakama</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

